Exploration of High Frequency Otoacoustic Emissions and Developmental Language Disorders
NCT ID: NCT05624983
Last Updated: 2022-11-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
138 participants
INTERVENTIONAL
2023-01-01
2027-07-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This obscures the importance of high frequencies (HF) which can be easily assessed by DPOAEs. In young children, the perception of these high frequencies could also play an important role in language acquisition.
The main objective of this study is to evaluate the relationship between subtle high-frequency hearing impairment, as assessed by the DPOAE (non-invasive, rapid and simple audiological test), and language delay or difficulties in a pre-, peri- and school-age pediatric population.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Tracking Early Emergence of Sound Perception Impairments in FXS With Multimodal fNIRS/EEG-Preschool Age
NCT05957549
Exposure to Intense and Prolonged Noises During Pregnancy
NCT05911204
Tracking Early Emergence of Sound Perception Impairments in FXS With Multimodal fNIRS/EEG- Infant
NCT06560242
Neonatal Hearing Screening in Assiut Hospital
NCT03251638
fNIRS in Pediatric Hearing Aids
NCT04696835
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Case group (children with language disorder)
Hearing diagnostic test
acoustic otoemisions
TOAE and DPOAE
Otoscopy
presence of earwax checked by video otoscop
Audiometry
Hearing Threshold will be measured with the AD528 interacoustics
Tympanometry
Tympanic mobility will be measyred with the Titan interacoustics
controle group (children without language disorder)
Hearing diagnostic test
acoustic otoemisions
TOAE and DPOAE
Otoscopy
presence of earwax checked by video otoscop
Audiometry
Hearing Threshold will be measured with the AD528 interacoustics
Tympanometry
Tympanic mobility will be measyred with the Titan interacoustics
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
acoustic otoemisions
TOAE and DPOAE
Otoscopy
presence of earwax checked by video otoscop
Audiometry
Hearing Threshold will be measured with the AD528 interacoustics
Tympanometry
Tympanic mobility will be measyred with the Titan interacoustics
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Free and informed consent of the parental authority and the patient
* Affiliated to the social security system
* Presenting a developmental language acquisition disorder (score according to the EVALO / EVALEO test)
* For children between 15 and 17 years of age, completion of the EVALEO test before their 16th birthday
* Normal hearing (after an audiometry test, even if an ENT consultation has been performed beforehand and if the doctor has not found any hearing problem, as defined in the NF EN ISO 70292017-04 standard, and according to an average hearing loss calculated according to the BIAP \<20dB HL)
* Free and informed consent of the parental authority and the patient
* Enrolled in the social security system
Exclusion Criteria
* Declaration by the parents of an ENT follow-up for a hearing disorder and/or a speech therapy for a language disorder
* Refusal of participation evoked by the subject
2 Years
17 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Clermont-Ferrand
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU Clermont-Ferrand, UMR INSERM 1107
Clermont-Ferrand, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RBHP 2022 SARRET
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.